Form 4: Zimmer Biomet Director Sreelakshmi Kolli Acquires Over 2,200 Equity Units

Zimmer Biomet Holdings, Inc. Director Sreelakshmi Kolli acquired 810.46 phantom stock units and 1,404.798 restricted stock units on May 29, 2025, as part of the company's deferred compensation and equity plans.

Summary

• Sreelakshmi Kolli, a Director of Zimmer Biomet Holdings, Inc. (ZBH), acquired 810.46 phantom stock units on May 29, 2025.
• These phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The phantom stock units are valued at $92.54 per unit and are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• The total beneficial ownership of phantom stock units following this transaction is 5,049.703 units, which includes 9.929 units accrued on April 30, 2025, from dividend reinvestment.
• Additionally, Ms. Kolli acquired 1,404.798 Restricted Stock Units (RSUs) on May 29, 2025.
• These RSUs are immediately 100% vested but are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.
• The total beneficial ownership of Restricted Stock Units following this transaction is 5,357.726 units, which includes units granted in prior years subject to different deferral periods.

Sentiment

Score: 7

Explanation: The acquisition of equity units by a director, even as part of a compensation plan, generally signals continued alignment of interests with shareholders and confidence in the company's long-term performance.

Positives

• The acquisition of additional equity units by a director, even as part of a compensation plan, aligns the director's interests more closely with those of the shareholders, potentially indicating confidence in the company's long-term performance.
• The immediate 100% vesting of the Restricted Stock Units provides a clear and immediate equity stake for the director.

Future Outlook

The phantom stock units are to be settled in shares of Company common stock within sixty days after the cessation of the reporting person's service as a Director. The Restricted Stock Units, while immediately vested, are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.

Industry Context

This Form 4 filing details a routine equity compensation grant to a non-employee director within the medical device industry. Such grants are common practice to align director incentives with shareholder value, reflecting standard corporate governance in the sector.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units and restricted stock units by Director Sreelakshmi Kolli from Zimmer Biomet Holdings, Inc. constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors under established compensation plans.

Stakeholder Impact

• Shareholders: The director's increased equity holdings through these compensation grants enhance alignment of interests, potentially leading to decisions that benefit long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Settlement of phantom stock units in common stock within 60 days after the director's cessation of service.
• Mandatory deferral of Restricted Stock Unit settlement until the later of the director's termination of service or three years after the grant date.

Key Dates

Recommendation

Keywords

Zimmer Biomet, ZBH, SEC Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, Restricted Stock Units, Equity Compensation, Corporate Governance